Modulators of ATP-binding cassette transporters
Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
1. A compound of formula IId:
or a pharmaceutically acceptable salt thereof; wherein
both R 2 groups, together with the atoms to which they are attached, form the group:
R′ 3 is selected from —CH 2 CH 2 and
and
each R 3 is independently selected from
H, and F.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R′ 3 is:
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein one occurrence of R 3 is fluoro.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein one occurrence of R 3 is
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein one R 3 is fluoro and one R 3 is
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof; wherein
both R 2 groups, together with the atoms to which they are attached, form the group:
R′3 is
and
one R 3 is fluoro and one R 3 is
7. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as described in claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
8. The pharmaceutical composition of claim 7 or a pharmaceutically acceptable salt thereof, wherein the composition further comprises one or more additional therapeutic agents.
9. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as described in claim 6 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
10. The pharmaceutical composition of claim 9 or a pharmaceutically acceptable salt thereof, wherein the composition further comprises one or more additional therapeutic agents.
11. A method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1 .
12. A method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 6 .